Vanguard Group’s Starling Oncology STLN Stock Holding History
Bought
Maintained
Sold
Other funds holding STLN
DM
CP
KWM
JAIC
WC
Vanguard Group's STLN Position: Q4 2025 in Review
Vanguard Group increased its Starling Oncology (STLN) stake by 4.5% in Q4 2025, buying an estimated $754K and bringing the position to 4,748,635 shares worth $16.9M. The position accounts for ﹤0.01% of the portfolio, ranked #2695.
Vanguard Group first reported a position in STLN in Q4 2021 and has held it in 17 quarters since. 117 funds tracked by Wall St. Rank hold STLN as of Q4 2025.
- Vanguard Group held 4,748,635 shares of Starling Oncology worth $16.9M as of Q4 2025.
- Vanguard Group bought 203,390 Starling Oncology shares in Q4 2025, an estimated $754K.
- Starling Oncology made up ﹤0.01% of Vanguard Group's portfolio in Q4 2025, its #2695 holding.
- Vanguard Group first reported a position in Starling Oncology in Q4 2021 and has held it in 17 quarters since.
- 117 funds tracked by Wall St. Rank held Starling Oncology as of Q4 2025.
Based on Vanguard Group's 13F filing for Q4 2025, filed 29 Jan 2026.